| Q4 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-02-07 | ||||||
| REV | |||||||
| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
You can purchase shares of Pear Therapeutics (NASDAQ: PEAR) through any online brokerage.
Other companies in Pear Therapeutics’s space includes: Sema4 Holdings (NASDAQ:SMFR), OptimizeRx (NASDAQ:OPRX), Definitive Healthcare (NASDAQ:DH), Better Therapeutics (NASDAQ:BTTX) and UpHealth (NYSE:UPH).
The latest price target for Pear Therapeutics (NASDAQ: PEAR) was reported by Credit Suisse on January 20, 2022. The analyst firm set a price target for 11.00 expecting PEAR to rise to within 12 months (a possible 162.53% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Pear Therapeutics (NASDAQ: PEAR) is $4.19 last updated Fri Jan 21 2022 21:00:04 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Pear Therapeutics.
Pear Therapeutics’s $Q4 earnings are confirmed for after-market on February 7, 2022.
There is no upcoming split for Pear Therapeutics.
Pear Therapeutics is in the Health Care sector and Health Care Technology industry. They are listed on the NASDAQ.